OnePlus 3 receives November security patch with OxygenOS 3.5.6 beta

Update, November, 19: Following a mix-up in OnePlus’ documentation, the 3.5.6 beta build of OxygenOS delivers the November security patch, not the October patch as previously reported.

OnePlus has released another beta build for its OnePlus 3 handset, but unfortunately there’s still no sign of Android 7.0 Nougat. Those eagerly awaiting that update should remain optimistic though, as it should land before the end of the year. Instead, the handset is being updated to OxygenOS 3.5.6 Beta 7, which packs a selection of notable new features and improvements.

The update weighs in at 1.5 GB, but there’s no major overhaul here. However, the update does include an entirely new audio tuner. This feature can be found under Settings > Sound > Audio. There’s also a background app freezing mechanism that should help to prolong battery life, along with tweaks to the UI’s clock and accent color.

As you would expect, there is also a selection of bug fixes included in this update too. The black screen issue that has been plaguing some gamers upon closing a title has been fixed, launcher related crashes should now be a thing of the past, and the update boasts an overall improvement to system stability.

As a beta update, this OTA will only roll out to those who have already enrolled into the beta branch, which you can still do if you want to be on the cutting edge of OnePlus 3 software. Don’t fret if you haven’t spotted the notification yet, OnePlus says that it will take a few days for the update to hit everyone around the globe.

Comments

The Secret Science 02:The 30 Most Disturbing Human Experiments in History

Disturbing human experiments aren’t something the average person thinks too much about. Rather, the progress achieved in the last 150 years of human history is an accomplishment we’re reminded of almost daily. Achievements made in fields like biomedicine and psychology mean that we no longer need to worry about things like deadly diseases or masturbation as a form of insanity. For better or worse, we have developed more effective ways to gather information, treat skin abnormalities, and even kill each other. But what we are not constantly reminded of are the human lives that have been damaged or lost in the name of this progress. The following is a list of the 30 most disturbing human experiments in history. 30. The Tearoom Sex Study Sociologist Laud Humphreys often wondered about the men who commit impersonal sexual acts with one another in public restrooms. He wondered why “tearoom sex” — fellatio in public restrooms — led to the majority of homosexual arrests in ...

The Strange and Stranger Case of Wyndham Lathem

A Northwestern University plague researcher has been charged with a brutal murder. Here’s what we know about him. WIKIMEDIA, TONY WEBSTER O n July 27, The Chicago Tribune reported that there was an arrest warrant issued for Wyndham Lathem , a microbiologist at Northwestern University. The crime Lathem would later be charged with was brutal—26-year-old Trenton James Cornell-Duranleau, whose body was found in Lathem’s apartment, had been stabbed dozens of times. But Lathem was nowhere to be found. As events unfolded over the following days, it became clear he had fled from Chicago to California with a second suspect, 56-year-old Andrew Warren, a University of Oxford employee from the United Kingdom visiting the states. Along the way, the two men apparently made an anonymous $1,000 donation in Cornell-Duranleau’s name to the Lake Geneva Public Library and another donation for $5,610 to a Chicago health center. Lathem had also sent a video to fa...

Popular painkiller doesn’t have more heart risks than others, study claims

NEW ORLEANS — A long-awaited study on painkillers called nonsteroidal anti-inflammatory drugs, the most widely prescribed class of drugs in the world, has concluded that the three most commonly used carry a similar risk of cardiovascular complications. Yet critics say the study was too flawed to fairly compare them. Concerns about a type of NSAID called COX-2 inhibitors peaked in 2004 when the drug Vioxx was withdrawn from the market — a decision steeped in scandal because manufacturer Merck & Co had initially hidden data that would reveal the drug’s cardiovascular risks. A second COX-2 inhibitor, Pfizer Inc.’s Celebrex, was allowed to remain on the market with the condition that Pfizer conduct a study to prove that Celebrex was no worse than two older NSAIDs, naproxen and ibuprofen. The study lasted 10 years and enrolled more than 24,000 patients, but faced challenges. Doctors in European Union countries would not participate because they were worried a...

The Research

Search This Blog